Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia

Cirmtuzumab is a humanized monoclonal antibody (mAb) that targets ROR1, an oncoembryonic orphan receptor for Wnt5a found on cancer stem cells (CSCs). Aberrant expression of ROR1 is seen in many malignancies and has been linked to Rho-GTPase activation and cancer stem cell self-renewal. For patients...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Stem Cell
Main Authors: Choi, Michael Y., Widhopf, George F., Ghia, Emanuela M., Kidwell, Reilly L., Hasan, Md Kamrul, Yu, Jian, Rassenti, Laura Z., Chen, Liguang, Chen, Yun, Pittman, Emily, Pu, Minya, Messer, Karen, Prussak, Charles E., Castro, Januario E., Jamieson, Catriona, Kipps, Thomas J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7001723/
https://ncbi.nlm.nih.gov/pubmed/29859176
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.stem.2018.05.018
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados